Development of ligand-targeted liposomes for cancer therapy.
about
Multiplexed imaging of surface enhanced Raman scattering nanotags in living mice using noninvasive Raman spectroscopyAdvances and Challenges of Liposome Assisted Drug DeliveryEmerging research and clinical development trends of liposome and lipid nanoparticle drug delivery systemsVascular targeting of nanocarriers: perplexing aspects of the seemingly straightforward paradigmNanomedicine and cancer immunotherapy: focus on indoleamine 2,3-dioxygenase inhibitorsLipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come.Phage protein-targeted cancer nanomedicines.Selection of pancreatic cancer cell-binding landscape phages and their use in development of anticancer nanomedicines.A novel assay for monitoring internalization of nanocarrier coupled antibodies.Identification and characterization of tumor antigens by using antibody phage display and intrabody strategies.Impact of single-chain Fv antibody fragment affinity on nanoparticle targeting of epidermal growth factor receptor-expressing tumor cells.Targeted drug delivery to mesothelioma cells using functionally selected internalizing human single-chain antibodiesLiposomes targeted by fusion phage proteinsEnhancement of cellular uptake and cytotoxicity of curcumin-loaded PLGA nanoparticles by conjugation with anti-P-glycoprotein in drug resistance cancer cells.Paclitaxel-loaded polymeric micelles modified with MCF-7 cell-specific phage protein: enhanced binding to target cancer cells and increased cytotoxicity.Enhanced binding and killing of target tumor cells by drug-loaded liposomes modified with tumor-specific phage fusion coat protein.Discovery of internalizing antibodies to tumor antigens from phage libraries.Immunoliposomal delivery of 213Bi for alpha-emitter targeting of metastatic breast cancer.On the mechanism of targeting of phage fusion protein-modified nanocarriers: only the binding peptide sequence mattersA First-Time-In-Human Phase I Clinical Trial of Bispecific Antibody-Targeted, Paclitaxel-Packaged Bacterial MinicellsComprehensive optimization of a single-chain variable domain antibody fragment as a targeting ligand for a cytotoxic nanoparticle.Non-affinity factors modulating vascular targeting of nano- and microcarriersImmunonanoshells for targeted photothermal ablation of tumor cellsA folate receptor-targeting nanoparticle minimizes drug resistance in a human cancer model.Tumor-specific antibody-mediated targeted delivery of Doxil reduces the manifestation of auricular erythema side effect in mice.Milatuzumab-conjugated liposomes as targeted dexamethasone carriers for therapeutic delivery in CD74+ B-cell malignancies.Characterization of highly stable liposomal and immunoliposomal formulations of vincristine and vinblastineEnhanced tumor delivery and antitumor activity in vivo of liposomal doxorubicin modified with MCF-7-specific phage fusion protein.Receptor-targeted nanocarriers for therapeutic delivery to cancer.The use of convection-enhanced delivery with liposomal toxins in neurooncology.Factors affecting the pharmacokinetics and pharmacodynamics of liposomal drugs.Prospects of nano-material in breast cancer management.Penetrating the cell membrane, thermal targeting and novel anticancer drugs: the development of thermally targeted, elastin-like polypeptide cancer therapeutics.Smart chemistry in polymeric nanomedicine.Targeted endothelial nanomedicine for common acute pathological conditions.Convection-enhanced delivery of targeted quantum dot-immunoliposome hybrid nanoparticles to intracranial brain tumor models.Immunoliposomal delivery of doxorubicin can overcome multidrug resistance mechanisms in EGFR-overexpressing tumor cells.Knockdown of vascular endothelial cell growth factor expression sensitizes U251 glioma cells to liposomal paclitaxel and radiation treatment in vitroEGFR-targeted immunoliposomes derived from the monoclonal antibody EMD72000 mediate specific and efficient drug delivery to a variety of colorectal cancer cells.B-cell receptor-guided delivery of peptide-siRNA complex for B-cell lymphoma therapy.
P2860
Q24651971-997EF70B-2795-4921-B3EF-D8756A9AC137Q26773160-82A3556B-7DDB-41D1-88CB-D104A68DD945Q26996159-B5EAC8D9-1128-4C52-AE4B-248919F00925Q27026630-6EC48786-F177-4A61-BD02-D17089904AAFQ28818166-C9EA103E-D8F5-4A34-88FF-9D5DA88CFDDFQ30366990-82C9E7D4-35D9-4E84-B648-2BE8C83705FCQ30403553-4EDE4B61-A277-4B70-AF1C-EECF876AA7D8Q31163147-34ABBD0E-4DFB-4842-AF29-37BA570AF05EQ33259109-86334F7E-799A-4B41-8A01-D603201CEB59Q33284494-B7C6D756-6B1B-4443-9465-B6832BB3B7C2Q33289414-1C1D1E6D-D406-4823-B1C4-265B43097CB8Q33322420-126FCAC8-EC8E-4B67-B264-463064CBEFD7Q33374206-27AAF818-65E5-4788-AE79-C44C72106FD8Q33567539-4257D9E7-CB56-453E-A2E7-0BFC3A4FA588Q33592506-D9C2A3B4-C83E-409F-B465-B1237D7C8C51Q33596415-B7C4BDD1-7A59-4B20-B606-143FB5E2FB74Q34114794-5E42BE8D-E3FC-492C-9C1D-0DF5B2A0D48FQ34296503-48BAAFE6-49E1-434D-8E2C-5D9C09E87C26Q35256650-809C1CFC-7C25-4229-94AD-AADE9A22DC23Q35867171-42A967EB-E0ED-42BF-96E1-FBBA7C8FB116Q36212921-0C370037-AE90-4D9D-A0E6-2E2BCDB6D173Q36703526-942ADB08-88FB-4075-83BE-A9E773E71A4DQ36717996-F1AE8034-0008-4849-A754-AC69CFF9160BQ37172880-0B288BE2-126A-477D-BE65-D3C598B1F374Q37188366-8CE9143F-BABE-4EB3-9440-690D5B550552Q37221480-A03C46F7-06F7-4133-AEC0-15EAB2F9CED2Q37279686-0453CE5A-5160-4CEA-897E-4B129F267F48Q37624040-20789A2F-647C-44FF-9180-5C571D595AEEQ37804383-4E16C7D3-F126-4F31-9BF6-37DF4780113EQ37954331-893B12B4-F153-49CC-ABAC-1DAB4296E788Q37983912-D9727A9D-06BC-4965-9F9F-EF94C4114E13Q38084156-66618DBE-9456-49F1-BA27-029E26F131D5Q38214156-E525EC0D-E7FB-4465-AF46-4254965F5C98Q38221776-331B094B-D1D8-4FC2-9316-8D0353FE0112Q38598987-20AF66FC-B350-4A5B-96F1-D22D7F765F42Q39158242-141C9769-3C72-4386-865B-FCC5E8877D29Q39361715-F3D418C9-AD64-4393-B1FF-41BC229E8A2CQ39554437-B921F2A8-1B10-4C17-BDFC-13B9209AF60AQ40267357-17F37C5C-991B-4D23-967E-DFBCF7D50C84Q40706746-905DAD6C-5E38-406A-BD2E-B9C2F70B2F4C
P2860
Development of ligand-targeted liposomes for cancer therapy.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Development of ligand-targeted liposomes for cancer therapy.
@ast
Development of ligand-targeted liposomes for cancer therapy.
@en
type
label
Development of ligand-targeted liposomes for cancer therapy.
@ast
Development of ligand-targeted liposomes for cancer therapy.
@en
prefLabel
Development of ligand-targeted liposomes for cancer therapy.
@ast
Development of ligand-targeted liposomes for cancer therapy.
@en
P2093
P356
P1476
Development of ligand-targeted liposomes for cancer therapy.
@en
P2093
Charles O Noble
Christopher C Benz
Daryl C Drummond
James D Marks
John W Park
Keelung Hong
Mark E Hayes
P304
P356
10.1517/14728222.8.4.335
P407
P577
2004-08-01T00:00:00Z